Condition
Super-refractory Status Epilepticus
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 3 (1)
Trial Status
Completed2
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07496749Not ApplicableRecruitingPrimary
KD Treatment for Super-refractory Status Epilepticus
NCT02477618Phase 3CompletedPrimary
A Study With SAGE-547 for Super-Refractory Status Epilepticus
NCT02052739Phase 1CompletedPrimary
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
NCT02433314UnknownPrimary
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
Showing all 4 trials